A new trading day began on Friday, with Cellectar Biosciences Inc (NASDAQ: CLRB) stock price down -5.45% from the previous day of trading, before settling in for the closing price of $0.44. CLRB’s price has ranged from $0.22 to $3.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 55.21%. With a float of $45.31 million, this company’s outstanding shares have now reached $46.08 million.
In an organization with 11 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cellectar Biosciences Inc (CLRB) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cellectar Biosciences Inc is 1.67%, while institutional ownership is 11.42%. The most recent insider transaction that took place on Jan 10 ’25, was worth 8,400. In this transaction Chief Operating Officer of this company bought 30,000 shares at a rate of $0.28, taking the stock ownership to the 83,141 shares.
Cellectar Biosciences Inc (CLRB) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 55.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.38% during the next five years compared to 40.27% growth over the previous five years of trading.
Cellectar Biosciences Inc (NASDAQ: CLRB) Trading Performance Indicators
Here are Cellectar Biosciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.54 in one year’s time.
Technical Analysis of Cellectar Biosciences Inc (CLRB)
Let’s dig in a bit further. During the last 5-days, its volume was 7.05 million. That was inferior than the volume of 7.54 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 39.57%. Additionally, its Average True Range was 0.05.
During the past 100 days, Cellectar Biosciences Inc’s (CLRB) raw stochastic average was set at 40.13%, which indicates a significant increase from 38.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 235.45% in the past 14 days, which was higher than the 116.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2893, while its 200-day Moving Average is $0.9104. However, in the short run, Cellectar Biosciences Inc’s stock first resistance to watch stands at $0.4398. Second resistance stands at $0.4663. The third major resistance level sits at $0.4837. If the price goes on to break the first support level at $0.3959, it is likely to go to the next support level at $0.3785. Assuming the price breaks the second support level, the third support level stands at $0.3520.
Cellectar Biosciences Inc (NASDAQ: CLRB) Key Stats
With a market capitalization of 19.04 million, the company has a total of 46,080K Shares Outstanding. Currently, annual sales are 0 K while annual income is -44,580 K. The company’s previous quarter sales were 0 K while its latest quarter income was -6,600 K.
